Takeda added some more firepower to the company’s immuno-oncology game on January 10 when the Japanese giant announced it will exercise an option to acquire U.K.-based Adaptate Biotherapeutics.

Amphivena Therapeutics Inc., a private clinical stage immuno-oncology company developing T-cell engager therapeutics for cancer, announced the closing of a $62 million Series C financing.